(Q54349324)

28 May 2018

title

Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. (English)

1 reference

28 May 2018

main subject

phase I clinical trial

0 references

author name string

J L Abbruzzese

1

1 reference

28 May 2018

S Schmidt

2

1 reference

28 May 2018

M N Raber

3

1 reference

28 May 2018

J K Levy

4

1 reference

28 May 2018

A M Castellanos

5

1 reference

28 May 2018

S S Legha

6

1 reference

28 May 2018

I H Krakoff

7

1 reference

28 May 2018

publication date

1 July 1989

1 reference

28 May 2018

Investigational New Drugs

published in

1 reference

28 May 2018

volume

7

1 reference

28 May 2018

issue

2-3

1 reference

28 May 2018

page(s)

195-201

1 reference

28 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00170857

exact match

0 references

cites work

High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study

1 reference

12 December 2020

Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides

1 reference

12 December 2020

Acute cerebellar dysfunction with high-dose ARA-C therapy

1 reference

12 December 2020

Fatal vidarabine toxicity in a patient with normal renal function

1 reference

12 December 2020

A Trial of Vidarabine for Cytomegalovirus Infection in Renal Transplant Patients

1 reference

12 December 2020

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

1 reference

12 December 2020

Cerebellar toxicity with high-dose cytosine arabinoside

1 reference

12 December 2020

A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.

1 reference

12 December 2020

Central nervous system toxicity with fludarabine

1 reference

12 December 2020

Diagnosis of dementia in cancer patients. Cognitive impairment in these patients can go unrecognized

1 reference

12 December 2020

Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-beta-D- arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5- iodocytosine

1 reference

12 December 2020

Biochemical effects of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil and 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mouse leukemic cells sensitive and resistant to 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system.

1 reference

12 December 2020

Activity of 2-fluoro-5-methylarabinofuranosyluracil against mouse leukemias sensitive to and resistant to 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Simple and choice reaction time in dementia: Clinical implications

1 reference

12 December 2020

The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication

1 reference

12 December 2020

Grading of neurotoxicity in cancer therapy

1 reference

12 December 2020

Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU).

1 reference

12 December 2020

Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C)

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00170857

1 reference

28 May 2018

1 reference

28 May 2018